Some intersting info in this. page 25 - assumptions re:...

Some intersting info in this.

page 25 - assumptions re: impairment of non-financial assets.

Forecast period is to 30 June 2027 with a forecast of 300 sales of units. Peak of 96 sales in peak year.

Sale revenue is $400k AUD and licence is $40k AUD per annum per licence. First year no licence fee, included in purchase price. Life of 6 years per instrument assumed.
Distributor fees 30% to 35%.

To june 2022 target is distributors on board, fully trained (by end 2021) with modest sales. Suppored by 3 x types of analysis modules Urine, MRSA and AMR. All moduiles to be cleared by december 2022 in all markets.

Page 26. Estimate of impairment item 1 (f). Notes terminal value at reduced ongoing sales projection of 20% of the year six peak sales, or 19 instruments. Also notes installment base of 115 units after reduction. Notes assumed licence fee of 5 renewals per unit following the year of sale.

BB share options page 38:
Target requires average of share price for 20 days up to option date.
Option is for shares at .16c.

30 June 2023: 2,000,000 options. Target to exercise option is .352c share price. Lower benchmark of 800,000 shares at .276c share price
30 June 2024: 2,000,000 options. Target to exercise option is .457c share price. Lower benchmark of 800,000 shares at .332c share price
30 June 2025: 2,000,000 options. Target to exercise option is .594c share price. Lower benchmark of 800,000 shares at .398c share price

DYOR. A little time and they may come good if the sales start flowing. If they come good there's no reason why this isn't sitting around .20c-.25c sometime later this year or early next.

See how it goes.